Neurodegenerative movement disorders arise when the brain's complex network of neural circuits begins to break down, disrupting the systems that control movement, cognition, speech and behavior. Conditions like Parkinson's disease often develop silently over years, with symptoms appearing only after significant neurological damage has already occurred.

As a result, researchers are increasingly focused on earlier detection and new ways to repair or modulate these damaged circuits using advanced technologies. Sean Pittock, M.D., is a physician-scientist and neurologist studying neurodegenerative movement disorders such as Parkinson's disease. He is the Glenn W. and Katherine K. Hasse Chair of Neurology at Mayo Clinic. Dr. Pittock shares insights on how research advances are shaping the future of diagnosis and treatment for these disorders.

Watch: Dr. Sean Pittock discusses technology to treat Parkinson's

Journalists: Broadcast-quality soundbites are available in the downloads at the bottom of the posts. Please courtesy: "Sean Pittock, M.D./Neurology/ Mayo Clinic."

Q: What are neurodegenerative movement disorders?

A: Neurodegenerative movement disorders are the result of the breakdown or dysfunction of normal neurological circuits in the brain that allow us to think, talk, hear, listen and move. There are many different types of these disorders, including Parkinson's disease, Huntington's disease, dystonia and essential tremor. Such disorders often culminate in memory problems, personality changes and abnormal body movements, with aging as a primary risk factor. 

Q: What makes neurodegenerative movement disorders particularly difficult to diagnose and treat?

A: These disorders often present with slowly progressive symptoms and are typically diagnosed with a range of tools, including blood tests, spinal fluid tests, imaging studies and psychometric testing. The challenge is that by the time a patient has symptoms we can diagnose, it is often late in the course of the illness. 

From a treatment perspective, we generally have supportive or symptomatic therapies, but we are working to get to the underlying cause. There has been progress, but what we're really focused on are ways to regenerate or help repair the broken circuits that drive these symptoms.

Q: Many people think of movement disorders as purely physical. How do movement and cognition overlap in these diseases?  

A: Neurodegenerative disorders affect neuronal circuits. In the brain, billions of nerve cells make trillions of connections, and those connections create the circuits that underlie movement, cognition, memory, executive function and speech. In these diseases, those circuits are damaged or dysfunctional. 

The circuitry involved in movement is often shared with the circuitry involved in thinking and memory, which is why patients may experience movement problems, cognitive changes, speech difficulties and gait problems together.

Q: What do patients and families experience that clinical measures don't capture well?  

A: The impact is much broader than any single symptom. Families often see the loss of independence, the loss of dignity, the loss of the person they knew, and the enormous burden of caregiving and support. Clinicians may focus on the visible issues — tremor, slowness of movement, cognitive dysfunction or difficulty communicating through language — but there are many other components to a human being that matter deeply. 

Q: What is the BIONIC Initiative, and how does it aim to improve care for patients with neurologic disorders? 

A: BIONIC (Bioelectronic Neuromodulation with Innovation to Cure) is designed to eliminate silos and create a fluid, team-science environment focused on solving common neurological problems. It grew out of the recognition that Mayo Clinic already had extraordinary expertise in neuroelectronics, neurology, neurosurgery, bioengineering and artificial intelligence, but that the next step was to bring everyone together under one umbrella. 

Q: What are your currently researching or testing that you're most excited about right now?  

A: In the case of Parkinson's disease, we know that implantable electrodes can dramatically reduce tremor and improve gait and daily function. We are now also exploring whether additional electrodes placed in other brain regions could help address other symptoms, such as sleep disorders, so that one surgical intervention could potentially address more than one major problem.

Q: How are new technologies — like precision neuromodulation — changing how you study or measure disease? And how are they being used in BIONIC research?  

A: New technologies are changing both how we intervene and how we measure disease. One major area is the ability to sense electrical activity in the nervous system and use AI to interpret that data in real time, enabling precision, closed-loop neuromodulation. 

Another is Mayo Clinic's BIONIC speech program. Our speech pathology team has extraordinary diagnostic expertise, and we are collecting patient speech samples to train AI to distinguish the speech patterns of one disease from another. The goal is to create a kind of "speech pathologist in your pocket" so that speech could help identify a likely neurodegenerative diagnosis before a patient even arrives, guide the evaluation that is organized for them, and monitor the rate of disease progression over time.

Q: Why is Mayo Clinic the right place for an initiative like BIONIC to take shape and succeed? 

A: Mayo Clinic is uniquely suited for BIONIC because multidisciplinary team science is central to how we operate. The strength here is not just that a bioengineer can build a device, but that the bioengineer can work directly with functional neurosurgeons, neurologists, speech pathologists, rehabilitation physicians, psychiatrists, sleep experts, data scientists and software engineers.

Mayo also has the AI infrastructure, neurosurgical expertise, and industry collaborations to accelerate innovation toward cure. 

Q: Looking ahead, what do you think will most change how we diagnose or treat neurodegenerative movement disorders in the next few years? 

A: The biggest changes are likely to come from more sophisticated neuromodulation and more individualized treatment strategies. In Parkinson's disease, we already know implantable electrodes with the right stimulation and oversight can markedly improve patients' lives, but the future may involve treating multiple symptoms with multiple electrodes in different parts of the brain rather than addressing only one symptom. 

Closed-loop systems — where we sense electrical information and respond in real time with a therapeutic impulse — also have enormous potential. At the same time, we need to expand noninvasive approaches, such as transcranial magnetic stimulation and other external stimulation methods, which may help patients who are not candidates for resection or implantable devices. 

The future will be about creating a playground where all modalities can be studied and matched to personalize care.

Related post:

• Advancing epilepsy care: Mayo Clinic neurologist Dr. Gregory Worrell 

Related Articles